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Abstract: A specific group of plant and animal oligosaccharides does not suffer enzymatic digestion 
in the human upper intestinal tract, achieving the colon microbial ecosystem in intact form. The reason 
for that is their diverse glycosidic bond structure, in comparison with common energetic 
polysaccharides as starch or glycogen. In this complex ecosystem, these molecules serve as energy 
sources, via fermentation, of distinctive beneficial bacterial groups, mainly belonging to the 
Anaerostipes, Bifidobacterium, Coprococcus, Faecalibacterium, Lactobacillus, Roseburia and other 
genera. The main catabolic products of these fermentations are short-chain fatty acids (SCFA) as 
acetate, propionate and butyrate, which appear in high concentrations in the lumen around the colon 
mucosa. Acetate and propionate are associated to energetic purposes for enterocytes, hepatocytes and 
other cells. Butyrate is the preferred energy source for colonocytes where it controls their cell cycle; 
butyrate is able to induce cell cycle arrest and apoptosis in tumor colonocytes. These oligosaccharides 
that increase beneficial colon bacterial populations and induce SCFA production in this ecosystem are 
called prebiotics. Here, different sources and chemical structures for prebiotics are described, as well 
as their modulatory effect on the growth of specific probiotic bacterial groups in the colon, and how 
their fermentation renders diverse SCFA, with beneficial effects in gut health. 
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1. The Prebiotic Concept 
The human gut tract is inhabited by a complex, diverse and highly metabolically active 
microbial community, called intestinal microbiota that comprises an extraordinary number (up to 100 
trillion cells and each person having around 200 prevalent species) of resident commensal   
bacteria [1,2]. Their combined genomes, known as microbiome, contain more than 5 million genes, 
thus outnumbering the host´s genetic potential by two orders of magnitude [3]. The microbiota plays 
a critical role in health and well-being of their host. Gut microbes facilitate nutrients and energy to 
the host, fermenting and absorbing undigested dietary components but also releasing a variety of 
metabolites including essential vitamins and short-chain fatty acids (SCFA) that influence locally 
and/or systemically host physiology [4,5]. At the same time, some intestinal microorganisms have 
the capacity for harmful effects, via their metabolic outputs and gene products (as H2S), or potential 
for pathogenicity [6,7]. 
Among other important functions, the gut community has a major role in control of epithelial 
cell proliferation/differentiation, confers protection against invasion by opportunistic pathogens and 
plays a key role in maturation of the immune system and host metabolism [8,9]. The overall balance 
of the gut microbial community in terms of its distribution, diversity, species composition and 
metabolic outputs is relevant in ensuring host homeostasis [5]. There is a large body of evidence 
linking alterations in the gut microbial composition, and the induced changes in interactions with the 
host, to several diseases [10], including obesity [11], inflammatory bowel disease (IBD) [12], 
cardiovascular disease [13], autoimmune arthritis [14] or colorectal cancer (CRC) [15,16]. Therefore, 
the extent to which the gut microbiota is clinically relevant to human diseases needs to be 
investigated more deeply. 
Nutrient availability is critical in influencing the composition and metabolic activity of gut 
microbiota [17]. Many studies have shown an increased proportion of bifidobacteria in breast-fed 
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infants compared to formula-fed infants due mainly to the presence of human milk oligosaccharides. 
A study over a period of 2.5 years of the gut microbiome in a single infant showed a gradual increase 
in diversity over time alongside abrupt shifts in the abundance of major taxonomic groups associated 
to changes in diet or health [18]. The most significant change in microbiome composition and 
functionality occurs during weaning with introduction to solid foods resulting in a shift within the 
early 2–3 years of life towards an adult microbiota [19].  
Dietary patterns have been demonstrated to affect the structure of the gut microbial community, 
having consequences in health and disease. Remarkably, some authors demonstrated that the 
composition of the intestinal microbiota differs significantly between children living in a rural 
African village and those living in Europe [20]. It has been shown that most diet-driven changes on 
microbiota occur rapidly and might reverse equally rapidly. Thus, short-term diets, such as those 
devoid of carbohydrates have been shown to have a pronounced effect on gut microbiome [21]. 
Shifting from a high-fat/low fiber diet to a low-fat/high-fiber diet caused significant changes in the 
gut microbiota within 24 h; however, the enterotype identity remained stable [22]. A diet rich in fruit 
and vegetable fiber has been associated with greater microbial diversity and might exert a positive 
influence in gut health [23]. In controlled human studies, variations in intake of resistant starch and 
non-starch carbohydrates induced significant changes in the gut microbiota and these seemed to be 
dependent of the initial composition of an individual´s gut microbiota [24]. Dietary supplementation 
with prebiotic fibers (as fructo-oligosaccharides and inulin) and dietary animal reduction can 
promote the growth of specific groups of bacteria, including bifidobacteria and Bacteroides, reducing 
simultaneously the relative amount of Firmicutes [6,25]. The presence of probiotics in milk products 
has been shown also to affect microbiota composition. Thus, higher consumption of fermented milk 
containing Lactobacillus helveticus in healthy subjects increased Bifidobacterium composition [26]. 
These relationships between diet and gut microbiomes are not only restricted to humans, as it 
has been shown that gut microbiome diversities from various vertebrates are adapted to the 
corresponding species diet (carnivorous, omnivorous, herbivorous). Thus, total protein intake in 33 
vertebrate species was associated with more metabolic functions encoded by gut microbiome genes 
(as proteases), whereas total insoluble dietary fiber was associated with higher diversity in microbial 
taxons. So, for each giving species, gut microbiome function and structure are associated with dietary 
intake. As an example, carnivorous gut microbiomes are shifted towards degradation of proteins and 
amino acids as energy source (conversion of mitochondrial pyruvate into oxaloacetic acid (OAA) 
devoted for energy generation in TCA cycle); whereas herbivorous ones are shifted towards 
biosynthesis of amino acids building blocks (generation of more pyruvate and phosphoenolpyruvate 
from OAA as building block for essential amino acids) [27]. In humans, links have been shown 
between people consuming more diverse insoluble dietary fiber (that one achieving the colon 
ecosystem and able to be fermented by this microbial community in order to produce SCFAs) and a 
healthier status with respect to western lifestyle autoimmune (Crohn’s disease, IBD) or inflammatory 
diseases (type 2 diabetes, insulin resistance, blood lipids concentrations, CRC, etc.) [28].  
It is well known that non-digestible food ingredients or substances are capable of modulating 
composition and metabolic function of gut microbiota, therefore preventing diverse infectious, 
inflammatory and neoplastic intestinal diseases [29]. These compounds are called prebiotics and 
since introduction of this concept, its definition has evolved over the last twenty years. In early 
studies, prebiotics were defined as “non-digestible food ingredients that beneficially affect host 
health by selectively stimulating the growth and/or activity of one or a limited number of bacteria in 
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the colon” [17]. The major beneficial effects of prebiotics seem to occur in the large intestine due to 
the slow transit of the substrates to be fermented and their effects on microbial diversity, which plays 
an important role in host health [30].  
 
Figure 1. Chemical structures of the different prebiotics families. FOS: 
fructo-oligosaccharides, GlOS: gluco-oligosaccharides, GOS: galacto-oligosaccharides, 
HMO: human milk oligosaccharides, IMO: isomalto-oligosaccharids.  
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More recently, prebiotics have been redefined as “selectively fermented ingredients that result in 
specific changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring 
benefit(s) upon host health” [31]. The metabolic end-products (as SCFAs) that result from this 
fermentation have been shown to exert beneficial effects, not only at large intestine but also within 
the entire human body and/or contribute to the prevention/remission of intestinal or systemic 
pathologies [32,33]. Indeed, the prebiotic definition is still matter of discussion and recently the 
concept has been revisited in an effort to shift the focus towards ecological and functional features of 
the microbiota more likely to be relevant in host physiology [34]. 
Prebiotics are, therefore, non-digestible oligosaccharides with various origin and chemical 
properties, differing in chain length, monosaccharide composition, linkage type and branching 
degree. Although there are several carbohydrates marketed as prebiotics worldwide, there are only a 
few oligosaccharides for which prebiosis has been clearly demonstrated in human intervention trials. 
These are inulin, oligofructose (also called fructo-oligosaccharides, FOS), galacto-oligosaccharides 
(GOS), the synthetic disaccharide lactulose (4-O-β-D-galactopyranosyl-D-fructose) and human milk 
oligosaccharides (HMO) [34] (Figure 1). Other candidate prebiotics are under investigation; among 
them, isomalto-oligosaccharides (IMO), arabino-oligosaccharides (AOS), xylo-oligosaccharides 
(XOS), gluco-oligosaccharides (GlOS), soy oligosaccharides and resistant starch have been regarded 
as emerging prebiotics that may show similar or improved properties than the market 
well-established oligosaccharides (Figure 1) [29,39,123].  
An aspect common to most of these prebiotic compounds is the fact that they mostly constitute 
carbohydrate energy reserves from diverse plant species, regardless of their accumulation in seed´s 
cotyledons (rye), leaves (agave), stems (artichoke), bulbs (garlic), roots (chicory) or tubers     
(yam) [63,123,161]. In contrast, with the most commonly widespread plant reserve carbohydrate, 
starch, which can also be found in seeds (maize), stems (sago), bulbs (onion), rhizomes (ginger), 
roots (cassava), tubers (potato) and fruits (banana) [36,56], prebiotics are not digested by mammalian 
enzymes responsible for starch degradation and absorption during intestinal digestion. Starch is 
usually composed of 30% amylose (long linear chains of glucose (linked through α-(1,4) bonds) and 
70% amylopectin (tridimensional complex networks of linear glucoses linked through α-(1,4) bonds 
and branched through α-(1,6) bonds to other linear chains) [9]. Mammals as humans degrade starch 
into glucose disaccharides (maltose) using the amylases produced from salivary glands and  
pancreas [4]. Then, the maltases produced at the enterocyte lumen degrade these maltoses, rendering 
free glucoses which are absorbed at the small intestine [55]. 
To exert their potentially prebiotic properties, oligosaccharides have to resist the digestive 
enzymes and survive, at least to some extent, the acidic environment and enzymatic digestion by 
pancreatic and intestinal brush border enzymes in the upper digestive tract. The oligosaccharides 
resistance to digestion is associated with several factors, including the identity of their monomeric 
units (fructose, xylose, galactose, arabinose, rhamnose, etc.), linkages type (as fructose chains linked 
by β-(1,2) bonds in inulin), as well as their ring form and anomeric conformation [21,68]. Dietary 
oligosaccharides that escape digestion and absorption in small intestine arrive at the colon and there, 
they are selectively fermented by a number of different bacterial populations, via competitive and/or 
cooperative interactions, giving rise to healthy metabolites, mainly SCFA as acetate, propionate and 
butyrate. Such modulatory effect on gut microbiota has been associated with improvement in overall 
health, enhancement of host defense mechanisms to gut infections, accelerated recovery of gut 
disturbances and better absorption of minerals [62]. 
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2. Structural Diversity of Prebiotics and Biological Activities 
The most widespread prebiotic compounds in nature are formed by fructose chains, where the 
monomers are linked by glycosidic β-(1,2) bonds. These polymers are called fructans, and their 
fructose chains may contain or not in one of its ends a glucose molecule. Linear fructan molecules 
may possess from 2 to more than 60 fructose moieties, calling them fructo-oligosaccharides (FOS) (2 
to 10 moieties) or inulin (more than 10 fructose residues, as in chicory (Cichorium intybus)) (Figure 
1) [21,31]. In about 10% of vascular plant species (like banana, garlic, onion and leek) this is the 
main energy reserve carbohydrate [48]. Several inulin types occur in nature and they differ in 
polymerization degree and molecular weight, depending on the source plant, harvest time and 
processing conditions [39]. 
Fructo-oligosaccharides (FOS) can be produced either by chemical degradation or controlled 
enzymatic hydrolysis of inulin by endoglycosidases [49]. Furthermore, FOS can be produced from 
sucrose at commercial scale, using fungal enzymes [50]. Several studies have shown the bifidogenic 
effect of inulin and FOS favoring Bifidobacterium and Lactobacillus growth, and decreasing that of 
Bacteroides and Clostridium [51]. 
Some arabino-oligosaccharides (AOS) from sugar beet pectin [52] and lemon peel [53] promote 
Bifidobacterium growth to the same extent as fructo-oligosaccharides (FOS) and inulin,  
respectively [54–57], with the highest bifidogenic response obtained with those having higher 
molecular weight [58]. These compounds are chains of L-arabinose moieties linked by α-(1,5) bonds, 
branched via α-(1,2) or α-(1,3) bonds with other L-arabinose moieties (Figure 1) [59]. The 
bifidogenic activity of high molecular weight rhamnogalacturonan I from potato pulp has been 
reported to be superior to the FOS one [60]. AOS fermentation may diminish the inflammatory 
conditions in ulcerative colitis (UC) patients. An in vitro approach to this has been carried out by 
fermenting AOS with fecal samples from UC patients and healthy control people. These experiments 
showed that AOS stimulated bacteria genera as Bifidobacterium and Lactobacillus, and an increase 
in SCFA as acetate, which are known to elicit anti-inflammatory responses. AOS may therefore 
represent a new prebiotic candidate for reduction of flare-ups risk in UC patients in the near future, 
once in vivo tests will be carried out [61]. 
Xylo-oligosaccharides (XOS), are sugar oligomers made up of xylose units. They are naturally 
present in fruits, vegetables, bamboo, honey and milk and can be produced at industrial scale from 
xylan-rich materials (as straw, wood and some macroalgae, where they form the hemicellulose 
portion). These unusual oligosaccharides are composed by chains of xylose moieties linked by β-(1,4) 
bonds, with a polymerization degree ranging from two to ten monosaccharides (Figure 1). Several 
studies have shown the bifidogenic effect of XOS [62,63]. They are considered soluble dietary fibers 
with prebiotic activity, favoring the improvement of bowel functions and immune function and 
having antimicrobial and other health benefits as being able to decrease blood glucose levels, total 
cholesterol and LDL in patients with type 2 diabetes mellitus [64]. 
Raffinose and stachyose (Figure 1) are non-digestible oligosaccharides present in soybean seeds 
but also in other legumes like peas or lentils. Raffinose is a trisaccharide containing a galactose 
moiety linked α-(1,6) to the glucose unit of sucrose. Stachyose is a tetrasaccharide containing a 
galactose molecule linked α-(1,6) to the terminal galactose unit of raffinose [65]. Deshipu stachyose 
granules is a novel oligosaccharide preparation (55.3% stachyose, 25.8% raffinose and 9.7% 
verbascose) which promotes the growth of beneficial intestinal bacteria in mice gut, inhibiting 
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pathogenic bacteria and also facilitating intestinal peristalsis and fecal excretion, thereby enhancing 
intestinal health and relieving constipation [66]. 
Resistant starch is present in some plants, where the starch amylose/amylopectin (Figure 1) 
relation is much higher than the usual 30%/70% respectively. This abundance facilitates the amylose 
crystallization and compaction processes, and hindering its digestion by amylases along the intestinal 
tract [67]. 
Galacto-oligosaccharides (GOS) are naturally-occurring compounds present in mammals’ milk. 
These prebiotics can be produced industrially from whey lactose by trans-galactosylation of lactose, 
carried out by β-galactosidases. This fact results in complex mixtures of oligosaccharides with 
different degrees of polymerization, ranging from two to eight moieties, and different glycosidic 
linkages: β-(1,1), β-(1,2), β-(1,3), β-(1,4) and β-(1,6) (Figure 1). Appropriate enzymes from different 
Bifidobacterium species can specifically hydrolyze these β-glycosidic linkages once they arrive at the 
colon [51]. Recently, the synthesis of lactulose-derived GOS has attracted the attention of the 
scientific community due to their prospective prebiotic applications, being recognized by their ability 
to promote the growth of bifidobacteria in vitro (human fecal slurries) [68] and in vivo (rat as a 
model) [46,69]. 
Human milk contains, apart from lactose (70 g/L) and GOS (5 g/L), other complex 
carbohydrates called HMO (human milk oligosaccharides, 10 g/L) that are important dietary factors 
with multiple functions during breast feeding ages [70,71]. HMO composition is very complex since 
at least may consist of more than 200 types of combinations of five monosaccharides: glucose, 
galactose, fucose, N-acetylglucosamine, and N-acetylneuraminic acid (Figure 1). Neutral HMO are 
composed by glucose and galactose but also contain multiple units of N-acetylglucosamine and 
fucose. Acid HMO contains, besides the above-mentioned carbohydrates, units of 
N-acetylneuraminic acid (also known as sialic acid). The presence of sialic acid and fucose in 
terminal positions render these polysaccharides non-digestible by human digestive enzymes. This 
facilitates its arrival to colon as unmodified carbohydrates, where they promote growth of diverse 
beneficial bacterial groups. In fact, HMO are responsible for the large numbers of Bifidobacterium 
present in breast-fed infants’ feces, as they get regular amounts of these prebiotics from mother´s 
milk [72,73]. In goat´s milk, the presence of other oligosaccharides (OS) similar to those found in 
human milk has been reported. Among them, i) the existence of neutral oligosaccharides, whose 
structures are mainly based on lactose with the addition of neutral monosaccharides such as glucose 
or galactose (Hex), N-acetylglucosamine or N-acetylgalactosamine (HexNAc) and  fucose or 
deoxyhexose (Fuc) and ii) acidic oligosaccharides, containing acidic components such as 
N-acetylneuraminic  (Neu5Ac) or N-glycolylneuraminic acid (Neu5Gc) [74]. Some of these 
oligosaccharides, such as those containing fucosyl- or sialyl- groups have been described to have 
prebiotic and/or pathogen binding activities [75]. 
Lactulose (4-O-β-D-galactopyranosyl-D-fructofuranose) is a synthetic prebiotic disaccharide 
composed of galactose and fructose linked by a β-(1,4) glycosidic bond (Figure 1), which can be 
industrially obtained by chemical isomerization of lactose present in whey permeate [76]. This 
enzyme-catalyzed synthesis offers new potential for food technology since it can be carried out with 
crude lactose materials derived from the dairy industry [77]. Lactulose shows bifidogenic properties 
stimulating the growth of health-promoting bacteria such as Bifidobacterium and Lactobacillus [78]. 
Lactulose is used not only in nutrition, as prebiotic, but also for treatment of chronic constipation at 
doses of 10 g/day [79], to maintain blood glucose and insulin levels [80], and to prevent hepatic 
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encephalopathy in liver failure patients, as lactulose reduces the intestinal absorption of toxic 
ammonium from lumen, preventing it from reaching the brain [81,82]. 
Isomalto-oligosaccharides (IMO) are a mixture of short-chain carbohydrates obtained 
enzymatically from starch. They contain α-(1,6) and α-(1,4) linkages (Figure 1) [30]. While human 
intestinal enzymes can digest α-(1,4)-glycosidic bonds, α-(1,6)-linkages are not easily hydrolyzed, 
and therefore they can reach the colon, where they are partially fermented by the microbiota [83]. 
Different studies have shown that IMO show bifidogenic properties [84,85,86]. IMO can also 
diminish total cholesterol and triacylglycerides levels in patients treated with hemodialysis [87] and 
stimulate intestinal and systemic immunity via a shift in the Th1/Th2 balance towards Th1-dominant 
immunity. Such effects may be due, at least in partially, to the relative increase of Lactobacillus 
numbers in the gut microbiota of mice [88]. 
Finally, gluco-oligosaccharides (GlOS) are glucose oligomers with α-(1,6) linkages that can also 
branch via α-(1,2) and α-(1,3) (Figure 1). These glycosidic linkages are resistant to hydrolysis by 
mammals’ digestive enzymes [89]. They can be produced from sucrose in the presence of maltose by 
enzymatic synthesis, or biosynthesized by Leuconostoc mesenteroides. In vitro fermentation studies 
have shown that they favor Bifidobacterium growth against harmful bacteria [90,91,92]. 
3. Modulation of Colon Microbiota by Dietary Prebiotics 
Once ingested, prebiotics can carry out a selective action for health-promoting taxonomic 
groups with beneficial metabolic activities [29]. In this sense, prebiotics might favor the growth of 
Bifidobacterium and/or Lactobacillus species in the colon, considered a major shift in gut microbiota 
towards a healthier composition. This overgrowth of such beneficial taxons inhibits the uncontrolled 
growth of undesirable, potentially pathogenic bacteria including Salmonella sp., Campylobacter 
jejuni, Helicobacter pylori and Escherichia coli, among others [51]. In a pioneered human study to 
demonstrate their bifidogenic effects, eight healthy volunteers having a controlled diet were 
supplemented with 15 g/day of oligofructose or inulin, both of which resulted in almost a ten-fold 
increase in luminal bifidobacteria, which then returned to baseline following withdrawal of the 
prebiotic supplement [93]. Since then, both prebiotics, and also GOS, have been used in many 
healthy human trials, with a general significant increase in colon bifidobacteria [94–100] 
Intestinal microbiota dysbiosis (an imbalance in body microbiota towards harmful species 
versus beneficial ones) scenarios are related to diseases as obesity, acting on the harvest and storage 
of dietary energy [101,102]. Dysbiosis is also a key factor in the development of inflammatory 
conditions as IBD [103,104] and Crohn’s disease, one of the main forms of IBD, which also shows 
an increased risk of CRC compared with healthy people [105]. Prebiotics can help in these cases, as 
for example, daily consumption of 15 g inulin in patients with Crohn’s disease improved disease 
symptoms and increased gut bifidobacteria [106]. 
Fecal microbiota diversity is reduced in cases of CRC, where is frequent the presence of 
opportunistic pro-inflammatory pathogens from Fusobacterium, Campylobacter, Collinsella, 
Peptostreptococcus, Porphyromonas, Mogibacterium and Anaerotuncus genera, as well as from 
Enterococcaceae and Erysipelotrichaceae families. In these cases there is also a reduction of 
Clostridium cluster IV members (as Faecalibacterium prausnitzii and Roseburia), and 
Bifidobacterium. Some of these taxons have been defined as CRC driver bacteria: those giving an 
advantage to tumor progression, as production of superoxide radicals (E. faecalis), genotoxic (E. coli 
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strains), toxigenic (B. fragilis) or pro-inflammatory compounds (Shigella, Citrobacter or Salmonella). 
NF-kB transcription factor is one of the main connections between these pro-inflammatory factors 
and CRC during its early stages, when inflammation induces genetic mutations, inhibits apoptosis 
and stimulates proliferation and angiogenesis [107]. 
Also, there is a potential role of the gastrointestinal microbiota in pathogenesis of irritable 
bowel syndrome (IBS), and in particular in its diarrhea-predominant type, where low numbers of 
bifidobacteria are found. This fact has suggested that by adding prebiotics in higher amounts in the 
diet of these patients, their symptoms could remit due to an increase in bifidobacteria    
populations [108]. A clinical trial using two different doses of GOS patients with IBS found an 
increase in the number of bifidobacteria in both groups, compared with the placebo group [109]. 
Apart from bifidobacteria, beneficial attributes are constantly discovered for many other gut 
bacteria, and there is ongoing debate on extending the range of target beneficial gut microorganisms. 
Thus, abundant species in the healthy microbiota such as Faecalibacterium prausnitzii, 
Eubacteriumrectale and Roseburia spp. have been reported to produce relatively high amounts of 
butyrate from prebiotics fermentation, which plays different roles in important processes linked to 
colonic health, including protection against inflammation and CRC [110].  
Furthermore, some studies have shown that CRC is related to variations in the amount of certain 
species of bacteria in the gut microbiota. For example, it has been reported a detectable increase in 
the diversity of the Clostridium leptum and Cl. coccoides subgroups in patients with CRC [111]. 
Differences in bacterial composition between healthy and tumor colon tissue have been described 
within cancer patients, with some genera of non-pathogenic bacteria, such as Coriobacteria, 
Roseburia, Fusobacterium and Faecalibacterium overrepresented in tumor tissue [112]. It has been 
observed that microbiota changes associated to CRC were not only limited to adenomas areas; as 
normal tissue beside tumors showed also increased levels of Proteobacteria and decreased levels of 
species in the Bacteroidetes phyla [113]. In other studies, the abundance of Bacteroides and 
Prevotella genera was higher in cancer tissue of patients than in adjacent normal tissue [114]. This 
later work is in accordance with a previous study where 15 colon microbial species were associated 
with an increased risk of cancer (including Bacteroides vulgatus, B. stercoris, Bifidobacterium 
angulatum and B. longum). In this previous study, higher levels or Bacteroides are expected in diets 
with high intake of red meat and fat, as both stimulates bile flow, which stimulates Bacteroides 
growth and are then converted by these bacteria into diverse colon mutagens. In this same study, 
Lactobacillus acidophilus and others, as well as Eubacterium aerofaciens were associated with a 
lower risk of the disease, likely due to their high production of SCFA as acetic acid. The presence of 
other bacteria, as Collinsella aerofaciens, has been also linked to a reduced risk of CRC [115]. In 
another study, patients with IBD showed lower levels of this species compared with normal subjects. 
The administration of inulin-type fructans increased levels of Co. aerofaciens, a considered 
beneficial effect associated with its fermentation [116]. 
4. Prebiotics Metabolic Effects and Their Catabolism by Gut Microbiome Species 
Prebiotics pass along our digestive tract free of enzymatic transformations, but once they arrive 
at the colon, these oligosaccharides are recognized as a suitable carbon source for diverse probiotic 
colonic bacteria, such as lactic acid bacteria of the genera Bifidobacterium and Lactobacillus, which 
generate large amounts of SCFA after their fermentation [117,118], mainly lactate, pyruvate, acetate, 
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propionate and butyrate, together with significant amounts of carbon dioxide and molecular 
hydrogen; and at lesser extent, formate, valerate and caproate (the former three accounting for less 
than 5% total SCFA). As an example, with a daily prebiotic fiber intake of 10 g, about 100 mmol of 
SCFA can be generated in the colon [49,119].  
Butyrate:propionate:acetate relative colon molar concentrations are 1:1:3. Butyrate is the most 
important SCFA in human health, as it is the preferred energy source of colonocytes, shows 
anti-inflammatory activity and regulates gene expression, differentiation and apoptosis in host colon 
cells. In contrast, acetate and propionate do not show a strong antitumor effect [120].  
Propionate is readily absorbed by enterocytes, passing to the portal vein circulation, and being 
taken up by the liver for gluconeogenesis purposes. Acetate is also rapidly absorbed, and distributed 
by peripheral blood to all tissues, where it is metabolized [121].  
Colon dysbiosis triggers alterations in the gut barrier function, allowing translocation to portal 
vein of bacterial components as lipopolysaccharides (LPS) and bacterial cells. Once distributed to 
other tissues, these pro-inflammatory factors promote local inflammation in liver and adipose tissue, 
giving rise to metabolic changes that may derive in obesity, metabolic syndrome and type 2 diabetes. 
These changes include higher circulating levels of triglycerides and free fatty acids, higher blood 
cholesterol levels, and insulin resistance in diverse tissues (muscle, liver, etc.). A first relationship 
between SCFA and metabolic syndrome derives from the observation that low SCFA blood 
concentrations have been associated to obesity status in laboratory animals and humans. SCFA can 
increase leptin levels in adipose tissue, a satiety hormone. At gut level, SCFA induce also production 
of GLP-1 hormone (glucagon-like peptide-1) after binding to GPR43 receptor. This mechanism 
increases insulin sensitivity. SCFA binding to gut GPR41 receptor induces PYY hormone (peptide 
YY) liberation. These two hormones act at the brain level by increasing satiety being at reduced level 
in obese individuals [119,122].    
Butyrate induces lipolytic activity in human adipocytes and in animal adipose tissue, mainly 
through lipoprotein lipase (LPL) transcription activation. SCFA bind to GPR43 receptor also in 
adipocytes, suppressing insulin signaling and therefore inhibiting fat accumulation and       
obesity [119,122].  
Acetate and propionate (the two main circulating SCFA) inhibit lipid accumulation in 
non-adipose tissues, as muscle, liver and pancreas. This inhibition helps in reducing side-effects (as 
local inflammation, insulin resistance and metabolic syndrome) caused by high levels of circulating 
fatty acids and triglycerides under metabolic syndrome circumstances. This effect seems to be 
associated with an increased fatty acid oxidation in these organs, and to the use of propionate for 
liver gluconeogenesis instead of using it for lipogenesis [119]. Acetate serum levels increase 
cholesterol biosynthesis, which is, however, inhibited by serum propionate [121]. 
SCFA increase the numbers of regulatory T cells, an anti-inflammatory cells with reduced 
numbers in obese individuals. Butyrate, for example, inhibits HDAC 6 and 9. This promotes histone 
H3 acetylation and expression of FoxP3 transcription factor, involved in development and function 
of these anti-inflammatory cells. This regulation on regulatory T cells may be of interest also in 
diseases as ulcerative colitis. Propionate regulates against allergic inflammations, hematopoiesis in 
the bone marrow and the proper function of dendritic cells. Also, SCFA improve epithelial barrier 
function and gut permeability, by modulating mucin and tight junction proteins        
expression [119,122,123]. 
Most butyrate producers are able to degrade complex polysaccharides towards monosaccharides 
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and glucose. For example, Roseburia intestinalis is a good colon xylan-degrading Firmicutes [124]. 
Roseburia is also a good producer of amylase for starch degradation, and some species can also 
degrade fructans as inulin, as in the case of R. inulinivorans and F. prausnitzii [125]. Fucose can be 
also a good metabolic substrate for fermentation by R. inulinivorans, in this case leading towards 
propionate formation instead of butyrate [126]. 
From these initial monomeric hexoses and pentoses, glycolysis pathway generates pyruvate, 
which is the substrate of pyruvate dehydrogenase decarboxylation, rendering acetyl-CoA [127]. 
Acetyl-CoA is then transformed into butyryl-CoA using diverse intermediates (acetoacetyl-CoA, 
3-hydroxy-butyryl-CoA and crotonyl-CoA) [110,128]. Starting from this acetyl-CoA, two main 
catabolic pathways, with no phylogenetic relationship, are involved in butyrate generation from 
prebiotic compounds in colon bacterial species. The most common one is the route using 
butyryl-CoA:acetyl-CoA transferase (BUT) as the final enzyme, generating acetyl-CoA and butyrate 
from acetate and butyryl-CoA precursors. This enzyme is present in many families belonging to the 
phylum Firmicutes, as Roseburia spp., Anaerostipes spp. (family Lachnospiraceae), 
Eubacterium.rectale, Eu. hallii (family Eubacteriaceae) and F. prausnitzii (family 
Ruminococcaceae). Also, other phyla share this pathway for butyrate production, as Actinobacteria, 
Bacteroidetes, Fusobacteria, Proteobacteria, Spirochaetes and Thermotogae [129–133]. 
An alternative pathway uses as final step for production of butyrate the enzymes 
phosphotransbutyrylase (PTB) for converting butyryl-CoA in butyrylphosphate and butyrate kinase 
(BUK) for transforming this in butyrate. However, this second pathway is very uncommon in human 
colon microbiota species, and has been identified for example in the Firmicutes bacteria Eu. 
ruminantium (family Eubacteriaceae), Coprococcus eutactus (family Lachnospiraceae), Cl. 
perfringens, Cl. beijerinckii, Cl. acetobutylicum, Cl. butyricum, Cl. eutactus and Cl. lituseburense 
(family Clostridiaceae) [134]. Interestingly, BUT pathway is more common in gut microbiota from 
omnivores and herbivores, whereas BUK route is more frecuent in carnivores [135]. Also, BUT 
pathway seems to be more effective under colon conditions, where acetate concentrations are usually 
high (more than 30 mM) [127]. 
SCFA biosynthesis is usually a complex phenomenon, as these taxons usually collaborate to 
degrade insoluble prebiotics towards SCFAs after several rounds of enzymatic transformations, as 
colon syntrophic consortia. For example, inulin is fermented by Bifidobacterium, generating acetate. 
Then, this SCFA, together with the preexisting endogenous lactate, is used by Clostridium cluster 
XIVa and Faecalibacterium praustnizii to produce butyrate. Another example is Roseburia 
inulinivorans and Faecalibacterium, which can collaborate to generate butyrate from inulin. Starch is 
degraded by Bacteroides spp., producing acetate and succinate, which is useful for other species as 
propionate precursor. Xylane is degraded by Roseburia intestinalis, producing H2 and CO2, which are 
converted by Ruminococcus hydrogenotrophicus into acetate [136]. 
5. Prebiotics as Effectors in CRC Prevention 
CRC is the most common cancer (35 cases per 100,000 hab) in western populations, and an 
important cause of death, after coronary heart diseases and lung cancer, followed by breast    
cancer [137]. Human populations with lower consumption of saturated fat and red meat, and higher 
levels of fruits and vegetables (good sources of prebiotic fibers leading to SCFA) show lower CRC 
incidences [138–141]. This has been also proof in animal models for CRC [142], as in murine 
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models treated with colon mutagens, the number of tumor lesions in colon mucosa decreased in rats 
fed inulin, most probably due to the production of butyrate [143,144]. 
CRC initiates in the colonic mucosa crypts, which cover this surface completely. These crypts 
are tubular invaginations formed by structured cell layers [145]. In the bottom of the crypt, stem cells 
are in charge of carrying out the processes of continuous cell division. This is necessary to maintain 
the structure and function of intestinal epithelium. Division of these stem cells gives rise to more 
stem cells or to already differentiated progenitor cells of the different cell types present in the colon. 
These progenitor cells are located in the intermediate area of the mucosal crypts, and their division 
and differentiation gives rise to differentiated cells found at the top of each crypt and the entire 
surface of the colonic mucosa. If one of these stem cells at the bottom of a crypt suffers mutations 
towards uncontrolled growth, their descendants will expand throughout the crypt, replacing normal 
stem cells and the rest of normal progenitor cells. This will eventually lead to an aberrant crypt, then 
to a microadenoma and to a large adenoma (polyp); and finally to an adenocarcinoma with metastasis. 
The entire development process can take over 30 years [146,147]. 
The most frequent mutations associated with CRC are those affecting cytoplasmic levels of 
β-catenin, a protein that normally is bound to E-cadherin in complexes. Free cytosolic β-catenin gets 
bound to ubiquitin in the Wnt-APC complex and is degraded by the proteasome. Defects in APC 
(very common in CRC cells) cause an increase in free cytosolic β-catenin, which is translocated to 
the nucleus, where it binds to transcription factors, activating cell proliferation, maintenance the 
pluripotency of cancer stem cells, increased motility and metastatic capacity [102]. The apc gene is 
mutated in many familial versions of CRC, as in FAP (familial adenomatous polyposis), and also is 
an acquired mutation in advanced steps of CRC transformation. Mutations in Mismatch Repair 
System genes (MLH, MSH2, MSH6 and PMS2) are present in patients with Lynch Syndrome, 
another familial version of CRC [148]. 
A 33% of CRC cells possess mutations causing permanent KRAS activation. This membrane 
GTPase therefore get independent from upstream growth factors signaling pathways and activates 
constantly other downstream proteins involved in cell growth, cycle progression at the G1/S phase, 
metabolic changes towards anabolism, angiogenesis development, cell immortalization and 
metastasis [149,150]. 
50%–80% of CRC cells show overexpression in MET (the hepatocyte growth factor receptor), 
which then activates constitutively other cell signaling pathways involved in motility and metastasis 
(as MAPK and PI3K-AKT-mTOR pathways) [151]. Other membrane receptors, as the human 
epithelial growth factor receptors HER1, HER3 and HER4 are overexpressed in 35%–89% of CRC 
cells, giving rise to poor prognosis, lower survival and metastasis respectively. Their activation in 
CRC induces also MAPK and PI3K-AKT-mTOR cell multiplication pathways [152,153,154]. 
Several studies suggest that butyrate is able to modulate the activity of NFkB (and some 
cytokines as TNF-), reducing the severity of colon inflammation associated to these transcription 
factor [155]. Butyrate inhibits specifically NFkB translocation to nucleus (which usually takes place 
once TNF- activates it). This exerts a potent anti-inflammatory effect. A low inflammatory status 
has been also associated to lower risk of CRC in several human studies [156,157,158]. 
In CRC cells, several anti-apoptotic factors, as BCL2A1, block BAK, inhibiting the apoptosis 
cascade; butyrate is also an inhibitor of BCL2A1 and other relatives [159]. In addition, CRC cells 
treated in vitro with butyrate overexpressed enzymes involved in the defense against genotoxic and 
mutagenic agents, which involves a protective effect of butyrate also at the level of detoxifying 
60 
AIMS Microbiology  Volume 1, Issue 1, 48-71. 
enzymes [160,161]. 
At the energetic metabolism level, butyrate is the main energy source for normal colonocytes, 
accounting for about 70% of all energy intake. At low concentrations and under reduced cytoplasmic 
levels of glucose and pyruvate (as in the crypts) butyrate acts as a normal growth and promoter for 
colonocytes [162,163]. In normal colonocytes, this intracellular butyrate concentration is maintained 
low because it is rapidly processed by -oxidation in the mitochondria, as the preferred energy 
source.  
However, in CRC cells, glucose is the main energy source. In these tumor cells, glucose uptake 
is increased about 10 times, due to overexpression of GLUT transporters and the Warburg effect 
taking place as in most of cancers. These cancer cells showing Warburg effect have increased levels 
of cytosol glycolysis, rendering huge amounts of cytosol pyruvate, which, instead of following the 
canonical aerobic oxidation process in mitochondria (Krebs cycle) is fermented anaerobically in 
cytosol to produce large amounts of lactate. This excess of glucose in CRC cells displaces butyrate as 
the main source of energy, and being butyrate accumulated in the CRC cell nucleus, causing histones 
hyperacetylation (as butyrate is a strong histone deacetylases (HDAC) inhibitor) and leading towards 
apoptosis induction, which proceeds via the intrinsic/mitochondrial pathway [163–167]. Histones 
acetylation is one of the main regulatory mechanisms to modulate genetic expression, not only in 
colonocytes but in other cell types. This acetylation alters the accessibility to DNA transcription, 
which is important in the processes of tumor formation [168]. Histone acetylation levels are 
dependent on histone acetyltransferases (HAT) and HDAC. Acetylation of histones H3 and H4 
neutralizes the positive charges in their lysine residues and disrupts the nucleosome structure, 
enabling DNA unfolding and a more relaxed chromatin structure; allowing access of transcription 
factors and activation of pro-apoptotic genes [169,170]. Interestingly, HDAC inhibitors, as butyrate, 
appear to be selective within the regions in which gene expression is altered; as in CRC cells [171]. 
Histone acetylation by butyrate (due to this nuclear HDAC inhibition) causes an increase in p21 
expression. p21 is an inhibitor of cyclin dependent kinases (CDKI) that plays a crucial role in cell 
cycle arrest at the G1/S phase in transformed cells and prevents tumor progression [172]. At the same 
time, the pro-apoptotic protein BAK is upregulated in the presence of high butyrate concentrations, 
and this protein is an essential issue for the apoptotic cascade in CRC cells. Both BAK and p21 
upregulation is caused by a less efficient binding of the Sp1 transcription factor to their promoter 
regions, allowing binding by Sp3 (coupled to HDAC1 and HDAC2) [170]. Sp3 then activates 
transcription of genes involved in blocking cell cycle at G2/M interphase, and also lnvolved in 
apoptosis induction (cytochrome C release from mitochondria, formation of APAP-1 complex, 
caspase 9 activation, etc.) [173,174]. 
Based on this, a few studies have been carried out in order to demonstrate if prebiotic 
consumption is able to reduce surrogate markers for CRC in humans. One study analyzed if 
consumption of prebiotic inulin (6 g, twice per day) caused a reduction in pre-neoplasic lessions in 
colon mucosa (aberrant crypt foci), but failed demonstrating a statistical reduction in this [175]. 
However, the European SYNCAN study showed a reduction in DNA damage and in fecal water 
genotoxicity in patients (which were actually surgically operated of previous colon polyps) receiving 
a symbiotic (prebiotic inulin plus two probiotics, B. lactis Bb12 and L. rhamnosus GG) [176]. Also, a 
reduction in genotoxic bile acids was observed in another human trial using oligofructose during a 
period of three months [177].     
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6. Conclusions 
Dietary intake of prebiotics has a major influence in the healthy status of the consumer. These 
nutraceuticals can be of plant origin (FOS, inulin, AOS, XOS, raffinose, stachyose, resistant starch), 
of animal milk origin (GOS, HMO), or generated by enzymatic industrial processes (lactulose, IMO, 
GlOS). Prebiotics are currently being extensively investigated by using a wide range of in vitro and 
in vivo approaches, not only as modulators of gut microbiota but also for their effects in a number of 
clinical conditions including CRC, intestinal disorders like ulcerative colitis, IBD and irritable bowel 
syndrome, prevention of obesity and constipation. The action mechanism/s by which these dietary 
oligosaccharides exert beneficial effects relays on their stimulation of the growth of colon probiotics 
and beneficial taxons with many anti-inflammatory capacities as well as in their catabolic products, 
especially butyrate, which is able to carry out a diverse and complex regulation of cell cycle in tumor 
colonocytes, leading towards their apoptosis. 
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